Tag: Synovial sarcoma immunotherapy

Home / Synovial sarcoma immunotherapy

Categories

The FDA has granted accelerated approval to afamitresgene autoleucel for the treatment of unresectable or metastatic synovial sarcoma

August 2024: The Food and Drug Administration has given accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a genetically modified autologous T cell immunotherapy that target...
synovial-sarcoma-immunotherapy

Scan the code